Core Insights - Orthofix Medical Inc. reported a Q3 2025 EPS of -$0.57, missing the estimated EPS of $0.12, but exceeded revenue expectations with approximately $205.6 million [1][5] - The company has adjusted its full-year 2025 net sales guidance and increased the lower end of its adjusted EBITDA guidance, indicating a strategic approach to future growth [2][5] Financial Performance - The negative price-to-earnings (P/E) ratio of -4.88 indicates negative earnings, while the price-to-sales ratio of 0.75 suggests the stock is valued at 75 cents for every dollar of sales [3][5] - The enterprise value to sales ratio is 0.92, reflecting the company's valuation in relation to its revenue [3] - The enterprise value to operating cash flow ratio is 25.92, showing how many times the operating cash flow can cover the enterprise value [4] - An earnings yield of approximately -20.50% emphasizes the negative earnings [4] - The debt-to-equity ratio of about 0.45 indicates a moderate level of debt compared to equity [4][5] - A current ratio of 2.67 suggests a robust ability to cover short-term liabilities with short-term assets [4][5] Strategic Considerations - The company is navigating challenges, including the discontinuation of its M6™ product lines, while its revenue performance and financial adjustments signal a strategic approach to future growth [4]

Core Points - Orthofix held its Third Quarter 2025 Earnings Conference Call, welcoming participants and introducing key executives [1] - The earnings release and supplemental presentation are available on the company's corporate website [1] - The call is being broadcast live and an archived copy will be accessible shortly after the call [2] Company Information - Julie Dewey serves as the Chief Investor Relations & Communications Officer for Orthofix [1] - Massimo Calafiore is the President and Chief Executive Officer of Orthofix [1] - Julie Andrews holds the position of Chief Financial Officer at Orthofix [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - Total global net sales reached $203.4 million, a 6% increase over the prior year, driven by strong performance in US spine and orthopedic segments [13] - Pro forma non-GAAP adjusted gross margin reached 72.1%, up 80 basis points from Q3 2024, driven by the discontinuation of M6 and productivity improvements [15] - Pro forma non-GAAP adjusted EBITDA was $24.6 million, or 12.1% of net sales, with year-over-year margin expansion of 230 basis points [16] - Generated positive free cash flow of $2.5 million, ending the quarter with $65.9 million in total cash [16] Business Line Data and Key Metrics Changes - US spine fixation segment net sales increased 8%, with procedural volume up 10% [5] - US orthopedics grew 19%, marking the fifth consecutive quarter of double-digit growth [9] - Bone Growth Therapies (BGT) achieved $61.2 million in net sales, reflecting 6% growth [15] Market Data and Key Metrics Changes - International spine fixation net sales grew by 86% year-over-year [14] - The US pedicle screw market, valued at approximately $2 billion in 2025, is projected to grow at a steady 4%-5% compound annual growth rate through 2030 [8] Company Strategy and Development Direction - Focus on sharpening commercial execution, improving gross margin, and maintaining disciplined capital allocation [10] - Advancing a data-driven deformity strategy with access to pre-operative planning and patient-specific roads beginning in Q1 of next year [9] - Aiming for a full launch of the Virada Spinal Fixation System in the second half of next year [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver strong operational and financial performance through the remainder of 2025 [19] - The company is well-positioned for its next phase of profitable growth with a streamlined product portfolio and optimized commercial channel [10] - Anticipated continued momentum in spine, BGT, and orthopedics businesses supported by a robust innovation pipeline [18] Other Important Information - The company is raising the bottom end of its full-year 2025 pro forma non-GAAP adjusted EBITDA guidance range to $84 million, with an updated range of $84 million-$86 million [17] - The guidance excludes revenue from the discontinued M6 product lines and implies fourth-quarter pro forma net sales will be approximately $219 million [17] Q&A Session Summary Question: Near-term revenue guidance and Q4 expectations - Management indicated that guidance was set appropriately, considering a strong Q4 last year and comparability issues [23] Question: Long-term financial targets for 2027 - Management suggested that growth will be more weighted towards 2027, driven by the full launch of Virada and continued acceleration of TrueLok Elevate [25] Question: Key drivers of strong results in US spine - Management identified three key points: distributor transitions, innovation pipeline, and the success of the 7D technology [32] Question: Q4 free cash flow expectations - Management expects to be free cash flow positive for the second half of 2025 but does not anticipate exceeding last year's Q4 figure [34] Question: Distributor transitions and increases - Management explained that the transition involves both consolidation and expansion of distributors to enhance market presence [37] Question: Clinical validation of TrueLok Elevate - Management expressed confidence in clinical validation efforts and the potential for more studies and publications in the future [40]

分组1 - Orthofix reported quarterly earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing an increase from $0.07 per share a year ago, representing an earnings surprise of +66.67% [1] - The company achieved revenues of $205.63 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.65% and increasing from $196.61 million year-over-year [2] - Over the last four quarters, Orthofix has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] 分组2 - The stock has underperformed, losing about 8% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $219.16 million, and for the current fiscal year, it is $0.54 on revenues of $812.83 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 38% of over 250 Zacks industries, indicating that the industry outlook can significantly impact stock performance [8]

Financial Performance - Net sales for Q3 2025 reached $205.634 million, a 4.2% increase from $196.606 million in Q3 2024[16] - Gross profit for Q3 2025 was $148.523 million, compared to $135.053 million in Q3 2024, reflecting a gross margin improvement[16] - Operating loss for Q3 2025 was $17.046 million, slightly improved from a loss of $18.899 million in Q3 2024[16] - Net loss for Q3 2025 was $22.795 million, compared to a net loss of $27.388 million in Q3 2024, indicating a reduction in losses[16] - The company reported a comprehensive loss of $23.069 million for Q3 2025, compared to a comprehensive loss of $25.559 million in Q3 2024[16] - For the nine months ended September 30, 2025, Orthofix reported a net loss of $89,970 thousand, an improvement from a net loss of $96,851 thousand in the same period of 2024[20] - Cash provided by operating activities was $5,650 thousand, compared to $2,060 thousand for the same period in 2024, indicating a significant increase[20] - Total revenues for the three months ended September 30, 2024, were $196,606 thousand, representing an increase from $205,634 thousand in the same period of 2025, which is a growth of approximately 4.2%[63] - Total net sales for the nine months ended September 30, 2024, were $583,834 thousand, which increased to $602,401 thousand in 2025, representing a growth of about 3.2%[64] Cost Management - Research and development expenses for Q3 2025 were $14.774 million, down from $17.294 million in Q3 2024, showing a focus on cost management[16] - Capital expenditures for the nine months ended September 30, 2025, were $23,749 thousand, slightly lower than $26,345 thousand in the same period of 2024[20] - The company incurred acquisition-related amortization and impairment of $3,120 thousand for the three months ended September 30, 2025, down from $4,551 thousand in 2024, reflecting a decrease of approximately 31.5%[65] Market and Growth Outlook - The company anticipates continued growth and market expansion, particularly following the merger with SeaSpine Holdings Corporation[13] - The company is focused on enhancing existing products and developing new products to drive future growth[13] - The Global Spine segment generated revenues of $172.063 million in Q3 2025, a 3.6% increase compared to $166.104 million in Q3 2024[53] - The Global Orthopedics segment saw a revenue increase of 10.1%, reaching $33.571 million in Q3 2025, up from $30.502 million in Q3 2024[53] Inventory and Cash Management - Total inventories decreased to $174,042 thousand as of September 30, 2025, down from $189,452 thousand at the end of 2024, reflecting a reduction of approximately 8.2%[28] - The company had cash, cash equivalents, and restricted cash of $65,946 thousand at the end of the period, compared to $32,554 thousand at the end of 2024, showing a substantial increase[20] - Cash and cash equivalents, along with investments, are expected to be sufficient to meet anticipated cash requirements[13] Legal and Compliance Matters - The Company is currently involved in multiple legal claims, including a securities class action complaint filed in August 2024, alleging violations of the Exchange Act[44] - The Company expects a final order from the arbitrator regarding the former executive's arbitration matter in the first quarter of 2026[42] - As of September 30, 2025, the company was in compliance with all required financial covenants under its $275 million secured credit agreement[31] Accounting and Reporting Changes - The company adopted ASU 2023-09 effective January 1, 2025, which enhances income tax disclosures but did not have a material impact on the financial statements[26] - Orthofix continues to evaluate the impact of recently issued accounting standards on its consolidated financial statements, indicating ongoing adjustments to financial reporting practices[27] Impairment and Valuation - The Company recorded an accounting accrual of $18.3 million for severance and equity-based rights owed to former executives in a "without Cause" termination scenario[42] - The impairment of developed technology amounted to $14,097 thousand for the nine months ended September 30, 2025, impacting acquisition-related amortization and remeasurement[75] - The estimated fair value of the Lattus Contingent Consideration as of September 30, 2025, was $7.3 million, down from $15.4 million at the beginning of the year[37] Shareholder and Equity Matters - The weighted average number of common shares outstanding increased to 39.519 million in Q3 2025 from 38.209 million in Q3 2024[18] - Share-based compensation expense for the three months ended September 30, 2025, was $7,181 thousand, compared to $6,531 thousand in 2024, reflecting an increase of approximately 9.9%[66] - The weighted average common shares outstanding for the three months ended September 30, 2025, increased to 39,766 thousand from 38,488 thousand in 2024, representing a growth of 3.3%[71] Product and Segment Performance - The Bone Growth Therapies product category achieved net sales of $61.211 million in Q3 2025, a 5.7% increase from $57.925 million in Q3 2024[53] - The Spinal Implants, Biologics, and Enabling Technologies category reported net sales of $110.852 million in Q3 2025, a 2.5% increase from $108.179 million in Q3 2024[53] - The Company accrued $10.3 million related to the IMDP as of September 30, 2025, classified within other long-term liabilities[51] - Adjusted EBITDA for the Global Spine segment was $30.642 million in Q3 2025, while the Global Orthopedics segment contributed $1.891 million, totaling $32.533 million[62]

Financial Performance (Q3 2025) - Reported net sales increased by 4.6% to $205.6 million compared to $196.6 million in Q3 2024[2,5] - Pro forma net sales (excluding M6 product lines) increased by 6.3% to $203.4 million compared to $191.3 million in Q3 2024[2] - Bone Growth Therapies net sales increased by 5.7% to $61.2 million[2] - Spinal Implants, Biologics and Enabling Technologies net sales increased by 5.6% to $108.6 million[2] - Global Orthopedics net sales increased by 10.1% to $33.6 million[2] - Adjusted EBITDA increased to $25.114 million, representing 12.2% of reported net sales, compared to $19.180 million or 9.8% in Q3 2024[7] - Pro forma adjusted EBITDA increased to $24.582 million, representing 12.1% of pro forma net sales, compared to $17.515 million in Q3 2024[7] Financial Performance (YTD 2025) - Net sales increased to $602.401 million from $583.834 million[5] - Adjusted EBITDA increased to $55.241 million, representing 9.2% of reported net sales, compared to $43.478 million or 7.4% in YTD 2024[7] - Free cash flow improved to -$18.099 million compared to -$24.285 million in YTD 2024[9] Balance Sheet (September 30, 2025) - Cash and cash equivalents totaled $62.860 million, down from $83.238 million at the end of 2024[3] - Total assets amounted to $832.610 million, compared to $893.294 million at the end of 2024[3]

Exhibit 99.1 News Release Orthofix Reports Third Quarter 2025 Financial Results LEWISVILLE, Texas — November 4, 2025 — Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's de ...

Core Insights - Orthofix Medical reported Q2 2025 results that modestly exceeded expectations for both GAAP earnings and non-GAAP revenue, with GAAP revenue of $203.1 million surpassing the analyst estimate of $196.19 million [1][2] - The company narrowed its net loss per share to $(0.36), better than the expected $(0.49), indicating operational improvements despite ongoing losses [1][2] - The quarter showed positive free cash flow of $4.5 million and a pro forma adjusted gross margin of 72.7%, reflecting incremental progress against operational and commercial goals [1][10] Financial Performance - GAAP revenue for Q2 2025 was $203.1 million, a 2.3% increase from $198.6 million in Q2 2024 [2] - Pro forma revenue (non-GAAP) reached $200.7 million, up 4.1% year-over-year from $192.8 million [2] - Pro forma adjusted net income (non-GAAP) was $4.6 million, a 39.4% increase from $3.3 million in Q2 2024 [2] Business Overview - Orthofix Medical specializes in medical devices and biologics for spine fusion, complex fracture management, and bone healing, with a diverse product mix including spinal hardware and bone growth stimulators [3] - The company focuses on three strategic areas: new product development, optimizing distribution through mergers, and managing regulatory requirements [4] Segment Performance - U.S. Spine Fixation net sales increased by 5%, with procedure volumes rising 7% year-over-year [5] - The Bone Growth Therapies segment reported pro forma net sales of $62.6 million, up 5.8%, with the AccelStim 2.0 device receiving regulatory clearance [6] - Global Orthopedics sales climbed 8.9% on a pro forma basis, with U.S. Orthopedics net sales growing 28% compared to Q2 2024 [7] Margin and Cash Flow - Gross margin expanded by 0.7 percentage points to 72.7% on a pro forma non-GAAP basis, aided by cost management and the discontinuation of low-margin products [10] - Free cash flow was positive at $4.5 million, with cash and equivalents increasing to $68.7 million as of June 30, 2025, up from $60.5 million at the end of Q1 2025 [10] Future Outlook - The company reaffirmed its full-year 2025 outlook, projecting pro forma net sales between $808 million and $816 million, representing approximately 5.0% constant currency sales growth [12] - Adjusted EBITDA (non-GAAP) is forecasted at $82 million to $86 million, with expectations for positive free cash flow excluding one-time restructuring costs [12]

Financial Data and Key Metrics Changes - The company's pro forma net sales for Q2 2025 reached $200.7 million, reflecting a year-over-year constant currency growth of 4% [7][23] - Pro forma non-GAAP adjusted gross margin improved to 72.7%, an increase of approximately 140 basis points compared to 71.3% in 2024 [29] - Pro forma non-GAAP adjusted EBITDA was $20.6 million, representing 10.3% of net sales, with an EBITDA margin expansion of approximately 190 basis points compared to 8.4% in 2024 [30] Business Line Data and Key Metrics Changes - U.S. Spinal fixation net sales grew by 5.4%, with procedure volume increasing by 7% [9] - Bone Growth Therapies (BGT) achieved net sales of $62.6 million, reflecting a 6% growth, with fracture growth within BGT at 7% [26][27] - U.S. Orthopedics grew by 28%, driven by the launch of the TRULOC Elevate system [15][28] Market Data and Key Metrics Changes - The international orthopedics business declined by 2%, attributed to the absence of large NGO orders that occurred in 2024 [29] - The U.S. market for complex limb reconstruction is valued at $1.7 billion, with the company aiming to become a market leader in this category [15][62] Company Strategy and Development Direction - The company is focused on three strategic priorities: enhancing commercial execution, improving gross margins, and disciplined capital allocation [19] - Recent product launches, including the Verada spinal fixation system and TRULOC Elevate, are expected to drive future growth [12][15] - The company aims to leverage its differentiated technology and strong surgeon relationships to enhance market penetration [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive profitable growth and deliver long-term shareholder value [8][36] - The company anticipates that the distributor transition will create a more robust commercial organization, paving the way for future growth [10][48] - Management highlighted the strong demand for the 7D flash navigation system and its role in driving sales growth [11][56] Other Important Information - The company expects full-year pro forma net sales between $800 million and $816 million, excluding revenue from discontinued M6 product lines [32] - Positive free cash flow of $4.5 million was generated in Q2, with expectations for continued positive cash flow throughout 2025 [30][34] Q&A Session Summary Question: What is driving the growth in U.S. Orthopedics? - Management indicated that growth is driven by both deeper utilization among existing customers and the introduction of new products like TRULOC Elevate, which addresses the diabetic foot market [39][40] Question: Is there guidance for CapEx in the second half? - Management noted that while CapEx was lighter than anticipated in Q2, it is expected to be heavier in Q3, with overall spending flat compared to last year [42][44] Question: How is the U.S. spine distributor transition progressing? - Management expressed satisfaction with the transition's execution and anticipates accelerated growth from Q3 onwards due to these efforts [48][49] Question: What is the status of the Xcelsim 2.0 launch? - The product has received FDA approval and is planned for launch in the second half of the year, with expected contributions to growth [50][51] Question: What impact did pricing have in Q2? - Management confirmed that pricing remained stable, with the majority of growth differences attributed to a significant customer impacting the spine fixation business [58][68]